Compare SDGR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDGR | MRVI |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2020 |
| Metric | SDGR | MRVI |
|---|---|---|
| Price | $17.99 | $5.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $21.00 | $4.13 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.14 | 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,869,000.00 | $185,743,000.00 |
| Revenue This Year | $0.76 | $12.54 |
| Revenue Next Year | $4.60 | $7.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.29 | N/A |
| 52 Week Low | $10.95 | $2.29 |
| 52 Week High | $23.02 | $7.44 |
| Indicator | SDGR | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 70.19 | N/A |
| Support Level | $17.26 | N/A |
| Resistance Level | $19.51 | N/A |
| Average True Range (ATR) | 0.72 | 0.00 |
| MACD | 0.28 | 0.00 |
| Stochastic Oscillator | 80.55 | 0.00 |
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.